<DOC>
	<DOC>NCT00810862</DOC>
	<brief_summary>Primecrolimus cream 1% is effective in the treatment of atopic dermatitis in African American children.</brief_summary>
	<brief_title>Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>African American children aged 2 to 17 years mild to moderate atopic dermatitis mEASI less than 3 at baseline allergy to Elidel or components use of oral steroids, immunosuppressive agents,cytostatics of phototherapy within 4 weeks prior to study. previous continuous or noncontinuous use of pimecrolimus or tacrolimus for greater than 11 months within 2 weeks of enrollment. active skin infections. immunocompromised patients. previous history of skin cancer or lymphoma any hypopigmentation in study areas pregnant or breastfeeding participation in another investigational trial</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>African American children</keyword>
</DOC>